EARNINGS & CATALYSTS · November 17, 2026
Medtronic earnings ahead on November 24: Hugo expansion meets a reshaped business
Medtronic reports before open on November 24. Expanded Hugo surgery clearance and the completed MiniMed separation put growth, spending and the new business mix in focus.

| Company | Report date | Window | EPS estimate | Revenue estimate |
|---|---|---|---|---|
| Medtronic Plc (MDT) | November 24, 2026Issuer confirmed | Before open | 1.33 | 9.48B |
1) When are earnings and what should investors compare?
Medtronic confirms fiscal second-quarter 2027 results on November 24, 2026, before open, covering the period ended October 30. The company also confirms a webcast that morning. Results remain upcoming. The most useful benchmark will be the outlook for the business after the completed MiniMed separation. September’s companywide adjusted earnings outlook of $5.94–6.00 per share was issued before that separation; it should not be treated as a restated forecast for the remaining business. Adjusted earnings exclude certain costs, while reported earnings follow standard accounting rules.
2) Why does the Hugo clearance matter?
On November 17, Medtronic announced FDA clearance for general surgery procedures using its Hugo robotic-assisted surgery system, expanding beyond its earlier U.S. urology indication. The covered procedures represent about 3.5 million U.S. surgeries annually, according to the company. That expands the potential market, but it is not a sales forecast: hospitals must adopt the system, train teams and use it regularly. The clearance arrived after the October 30 quarter-end, making it an outlook catalyst rather than an explanation for revenue already earned in the coming report.
3) How do the last two reports compare with expectations?
Fiscal fourth-quarter 2026 sales were $9.807 billion and adjusted earnings per share, or EPS, were $1.55. Compared with Zacks estimates dated May 27, revenue was 1.5% above $9.66 billion and EPS was 0.6% below $1.56. Fiscal first-quarter 2027 sales of $9.756 billion and adjusted EPS of $1.45 were 3.0% and 4.3% above the August 25 estimates of $9.47 billion and $1.39. These deliberately dated, week-earlier estimates can differ from the final consensus on release day. Reported EPS was $0.96 and $1.14 respectively. Both quarters included the diabetes business. The first quarter also contained an extra fiscal week, which management estimated added about $570 million of revenue to its organic-growth calculation.
4) What does the price chart show?
Medtronic closed at $102.32 on November 17, 2026, above its 20-day average of $99.35 and 50-day average of $94.10. Recent lows suggest an approximate $100–101 support area, while early-November highs sit around $105–106. These are reference areas, not guaranteed turning points. Shares rose 5.7% from the June 2 close to the June 3 close after the fourth-quarter release, and 1.5% from the August 31 close to the September 1 close after the first-quarter release. Those full-day changes also reflect other market influences.
5) How should the financial images be read?
The five-year revenue history and fiscal 2026 business mix describe Medtronic before the MiniMed separation. They are not a forecast of the remaining company’s revenue. The illustrative equity value uses the November 17 closing price and August 28 outstanding shares, less the shares accepted in October’s exchange offer; it excludes other subsequent share changes. Valuation multiples are omitted because mixing a changed share count and business portfolio with older earnings could give a misleading comparison.
6) How the business makes money
Medtronic sells medical equipment, implants and related supplies used in heart care, spine and brain treatment, and surgery. Product adoption depends on clinical evidence, physician training, hospital budgets and reimbursement. Equipment placements can create further demand for instruments and supplies, so procedure usage matters alongside initial system sales.
7) What to watch
The central earnings question is how the remaining company converts its product pipeline into profitable growth. New Hugo indications expand the procedures it can serve, while heart-rhythm and ablation products offer another growth opportunity. Watch management’s explanation of underlying demand after last quarter’s extra fiscal week, launch spending, cash generation and the earnings effect of the completed MiniMed exchange. A clearer outlook could help investors assess the new business mix.
8) Recently reported peers
Boston Scientific provides relevant context through competing cardiovascular, neuromodulation and surgical-device businesses. On October 28 it reported third-quarter sales of $5.138 billion and adjusted EPS of $0.73, below Zacks estimates dated October 21 of $5.17 billion and $0.76 by 0.6% and 3.9%. Reported EPS was $0.40. It described a cyber incident that disrupted operations and issued fourth-quarter guidance for a 1–3% sales decline and adjusted EPS of $0.77–0.79. Shares fell 5.8% from the October 27 close to the October 28 close. Its company-specific disruption is a reminder to examine execution and product competition; it does not establish what Medtronic will report.
9) Risks into the report
Hospital purchasing delays, reimbursement changes, product safety issues and intense competition can slow adoption. Launch costs, acquisitions and tariffs can reduce the profit earned on higher sales. Separating MiniMed also changes revenue, earnings and shares outstanding, making headline year-over-year comparisons less useful until the continuing-business figures are reconciled. FDA clearance expands permitted use but does not guarantee commercial success.
10) Insider activity over the past three months
$0 bought and $5.89M sold in reported trades. 0% buy / 100% sell by value. 0 insiders bought only, 3 sold only, and 0 did both.